Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of methadone due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of oxycodone due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Avoid combination - decreased level of palbociclib due to 3A4 induction. Choose an alternative agent.
Avoid combination - decreased level of palbociclib due to 3A4 induction. Choose an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of simvastatin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
No clinically significant drug interactions identified.
Caution - increased level of both agents due to 3A4 inhibition. Monitor for signs of toxicity. Consider choosing an alternative agent.
No clinically significant drug interactions identified.



